title: Human glioma cell lines: tumour associated antigens distribution and sensitivity to antibody-toxin or ligand-toxin conjugates. A preliminary report.
abstract: We have investigated the phenotype of seven human glioma cell lines established in vitro from primary tumour explants. Indirect immunofluorescence and flow cytofluorimetry revealed a heterogeneous distribution of surface GE 2 and CG 12 Tumour Associated Antigens (TAA). In one group of cell lines TAA were detected both at the cell surface and in the cytosol, whereas in a second group of glioma cell lines TAA were found only in the cytosol. We have also investigated the sensitivity of glioma-derived cell lines to antibody-toxin and ligand-toxin conjugates (Immunotoxins). Monoclonal antibodies anti GE 2 antigen linked to ricin toxin A subunit (RTA) showed poor cytotoxicity, which increased about 50 fold when the whole toxin was linked to anti GE 2 monoclonals. Treatment with human recombinant interferon gamma (IFN-gamma) greatly augmented the percentage of HLA-DR+ cells and the amount of HLA-DR antigens per cell. IFN-gamma treatment resulted in a net increase of sensitivity to anti HLA-DR Immunotoxins (IT). Human diferric transferrin linked to RTA exhibited a potent cytotoxic effect against human glioma-derived cells when used in the presence of the lysosomotropic carboxylic ionophore monensin.
authors.affiliation: Istituto di Scienze Immunologiche, University of Verona, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Colombatti
authors.forename: M
authors.initials: M
authors.lastname: Bisconti
authors.forename: P
authors.initials: P
authors.lastname: Lorenzi
authors.forename: G
authors.initials: G
authors.lastname: Stevanoni
authors.forename: B
authors.initials: B
authors.lastname: Dipasquale
authors.forename: M
authors.initials: M
authors.lastname: Gerosa
authors.forename: G
authors.initials: G
authors.lastname: Tridente
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology; D000951:Antigens, Neoplasm / Q000032:analysis* / Q000276:immunology; D004357:Drug Synergism; D005910:Glioma / Q000276:immunology* / Q000378:metabolism; D006801:Humans; D000922:Immunotoxins / Q000494:pharmacology*; D008985:Monensin / Q000494:pharmacology; D014176:Protein Biosynthesis; D011506:Proteins / Q000037:antagonists & inhibitors; D012276:Ricin / Q000494:pharmacology; D014168:Transferrin / Q000494:pharmacology
chemical_list: D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D000922:Immunotoxins; D011506:Proteins; D014168:Transferrin; C028283:diferric transferrin; D012276:Ricin; D008985:Monensin